BDTX’s Market Ups and Downs: What’s Behind the 2025 Stock Performance?

HCCC Stock

The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -56.98%.However, over the last six months, we can see a stronger performance of -16.18%. Over the last 30 days, the price of BDTX has leaped by -13.64%. And in the last five days, it has fallen by -14.29%.

At present, Black Diamond Therapeutics Inc (BDTX) has a stock price of $2.28. In the previous session, the stock saw a rise, peaking at $12.0 after an opening price of $2.28. The day’s lowest price was $9.0, and it closed at $2.69.

Black Diamond Therapeutics Inc’s market performance has been stable in recent times.

52-week price history of BDTX Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Black Diamond Therapeutics Inc’s current trading price is -66.22% away from its 52-week high, while its distance from the 52-week low is 90.79%. The stock’s price range during this period has varied between$1.20 and $6.75. The Black Diamond Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.87 million for the day, a figure considerably higher than their average daily volume of 1.17 million over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Black Diamond Therapeutics Inc (BDTX) has experienced a quarterly rise of 47.10% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 129.65M and boasts a workforce of 24 employees.

Black Diamond Therapeutics Inc: Analysts’ Ratings Unveiled

As of right now, 3 analysts are rating Black Diamond Therapeutics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 2.14, with a change in price of +0.56. Similarly, Black Diamond Therapeutics Inc recorded 2,628,363 in trading volume during the last 100 days, posting a change of +32.56%.

BDTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BDTX stands at 0.15. Similarly, the long-term debt-to-equity ratio is also 0.13.

BDTX Stock Stochastic Average

As of today, Black Diamond Therapeutics Inc’s raw stochastic average for the last 50 days stands at 24.18%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 5.48%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 18.65% and 26.61%, respectively.

Invest Chronicle
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.